Back to Search
Start Over
Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.
- Source :
-
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [J Clin Virol] 2024 Aug; Vol. 173, pp. 105661. Date of Electronic Publication: 2024 Feb 28. - Publication Year :
- 2024
-
Abstract
- Background: Various SARS-CoV-2 variants of concerns (VOCs) characterized by higher transmissibility and immune evasion have emerged. Despite reduced vaccine efficacy against VOCs, currently available vaccines provide protection. Population-based evidence on the humoral immune response after booster vaccination is crucial to guide future vaccination strategies and in preparation for imminent COVID-19 waves.<br />Methods: This multicenter, population-based cohort study included 4697 individuals ≥18 years of age who received a booster vaccination. Antibody levels against SARS-CoV-2 receptor binding domain (RBD) and neutralizing antibodies against wild-type (WT) virus and Omicron variants were assessed at baseline (day of booster vaccination) and after four weeks. Safety was evaluated daily within the first week using a participant-completed electronic diary. Antibody levels were compared across different vaccination strategies, taking into account individual host factors.<br />Results: Our main model including 3838 participants revealed that individuals who received a booster with mRNA-1273 compared to BNT162b2 vaccine had a significantly higher increase (95 %CI) in anti-RBD-antibody levels (37,707 BAU/mL [34,575-40,839] vs. 27,176 BAU/mL [26,265-28,087]), and of neutralization levels against WT (1,681 [1490-1872] vs. 1141 [1004-1278] and Omicron variant (422 [369-474] vs. 329 [284-374]). Neutralizing antibody titres highly correlated with anti-RBD antibodies, with neutralizing capacity 4.4 fold higher against WT compared to Omicron. No differences in safety were found between the two booster vaccines.<br />Conclusion: Our study underlines the superiority of a booster vaccination with mRNA-1273, independent of the primary vaccination and therefore provides guidance on the vaccination strategy.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024. Published by Elsevier B.V.)
- Subjects :
- Humans
Male
Female
Middle Aged
Adult
Aged
Cohort Studies
Vaccination
Spike Glycoprotein, Coronavirus immunology
Young Adult
Immunization, Secondary
COVID-19 prevention & control
COVID-19 immunology
Antibodies, Neutralizing blood
Antibodies, Viral blood
SARS-CoV-2 immunology
COVID-19 Vaccines immunology
COVID-19 Vaccines administration & dosage
COVID-19 Vaccines adverse effects
Immunogenicity, Vaccine
BNT162 Vaccine immunology
BNT162 Vaccine administration & dosage
2019-nCoV Vaccine mRNA-1273 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1873-5967
- Volume :
- 173
- Database :
- MEDLINE
- Journal :
- Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
- Publication Type :
- Academic Journal
- Accession number :
- 38503118
- Full Text :
- https://doi.org/10.1016/j.jcv.2024.105661